Background
==========

There has been a resurgent interest in the use of hyperventilation to hasten recovery from general anesthesia \[[@B1]-[@B5]\]. Hyperventilation during emergence allows faster removal of the potent inhaled anesthetic from the lungs and body and results in a lower alveolar concentration, but the ensuing hypocarbia decreases removal of the agent from the central nervous system (CNS) through its effect on cerebral blood flow (Q~CNS~) \[[@B4]\]. In order to maintain normocarbia (and thus Q~CNS~) during hyperventilation (= normocarbic hyperventilation), several techniques have been used such as the addition of exogenous CO~2~ to the fresh gases, or rebreathing of CO~2~ by reducing fresh gas flow (FGF) while the anesthetic agent is eliminated via an activated charcoal filter. But even regardless of the potential technical hurdles to maintain normocarbia during hyperventilation, is normocarbic hyperventilation even worth it in terms of speeding up recovery? We argue that the benefit of hyperventilation on speed of recovery is predictably small with modern potent inhaled anesthetics because of their low solubility \[[@B6],[@B7]\]. Also, the effect of hyperventilation is likely to depend on the duration of administration of the agent \[[@B6],[@B7]\]. In particular, the situation in which the muscle group (MG) would have been saturated intrigued us because a short period of hyperventilation may result in less wash-out of the agent from the saturated muscle group (MG); subsequently, when normoventilation returns or when hypoventilation occurs, the higher partial pressure in the MG could theoretically result in redistribution of a larger amount of agent to the vessel rich group (VRG; including the CNS), resulting in rehypnotization (defined as an increase in F~VRG~ \>0.3 MAC). This potential detrimental effect of initial hyperventilation has not been addressed previously, theoretically nor clinically. We therefore used GasMan^®^ simulations to help demonstrate and clarify these two issues: does normocarbic hyperventilation shorten emergence substantially with modern low-soluble agents, and what is the risk of rehypnotization when subsequent hypoventilation occurs?

Methods
=======

GasMan^®^ (Version 4.0.0, Med Man Simulations, Inc., Chestnut Hill, MA), a computer program, is a physiologically-based model of inhaled anesthetic uptake and distribution. Agent solubility in blood and tissues, gas and blood flows, and compartment volumes (lungs, VRG, MG, and fat group) determine the rate of agent transfer \[[@B8]\]. The version used in this study does not correct for inter-tissue diffusion, anesthetic metabolism, dead space, or ventilation/perfusion abnormalities. In addition, several assumptions are made within GasMan^®^: increasing alveolar minute ventilation (V~A~) does not change the arterial partial pressure of CO~2~ (=normocarbic hyperventilation); F~VRG~ is representative for the partial pressure in the central nervous system, F~CNS~; the brain is a homogeneous tissue, even though gray matter and white matter have different perfusion and agent solubility; and the effect of age and other factors on MAC are ignored. MAC values that we used in our GasMan^®^ simulations are: desflurane 6%, sevoflurane 2%, isoflurane 1.2%. The GasMan^®^ program allows the user to manipulate the vaporizer setting (F~D~) of an agent of choice, FGF, circuit volume, V~A~ and cardiac output, and to observe the resulting course of inspired and alveolar partial pressure (F~I~ and F~A~, respectively) and the partial pressure of the potent inhaled anesthetic in several tissues (arterial and venous blood, VRG, MG and fat group \[F~a~, F~v~, F~VRG~, F~MG~, and F~fat~, respectively\]). GasMan^®^ simulations have been used to study the effect of solubility, cardiac output, and duration of anesthesia on the kinetics of the potent inhaled anesthetics during emergence \[[@B9]-[@B11]\].

The following GasMan^®^ program settings were kept constant for all simulations (unless stated differently): a 70 kg patient, an anesthesia breathing circuit volume of 8 L, a FGF of 1 L.min^-1^, an alveolar minute ventilation (V~A~) of 5 L.min^-1^, a functional residual capacity (FRC) of 2.5 L, and a cardiac output (Q) of 5 L.min^-1^. Other GasMan^®^ settings and parameters are presented in Table [1](#T1){ref-type="table"}.

###### 

**GasMan**^**®**^**settings and parameters**

                     **Blood**   **VRG**   **Muscle**   **Fat**
  ----------------- ----------- --------- ------------ ---------
  *λ* desflurane       0.42       0.54        0.97        13
  *λ* sevoflurane      0.65        1.1        2.4         34
  *λ* isoflurane        1.3        2.1        4.5         70
  Volume (L)                        6          33        14.5
  Blood flow (%)                  75.8         18          6

*λ*: tissue/gas partition coefficient; VRG: vessel rich group.

In GasMan^®,^ isoflurane, sevoflurane, or desflurane were administered to attain an F~A~ of 1 MAC for 8 h, resulting in complete saturation of the VRG and near-complete saturation of the MG. Even with the low FGF of 1 L.min^-1^, F~A~ was reached fairly rapidly by using overpressure (F~D~ desflurane of 18%; F~D~ sevoflurane of 5%; F~D~ isoflurane of 3%). At the end of 8 h, with the MG \>95% saturated, administration of the agent was terminated, and FGF was increased to 10 L.min^-1^ to avoid rebreathing. For each agent, we had one simulation with normoventilation (V~A~ 5 L.min^-1^) and another one with hyperventilation (V~A~ 10 L.min^-1^). We determined the time for the F~VRG~ (representing F~CNS~) to reach 0.3 MAC, which was considered to be MACawake. After F~VRG~ reached MACawake, besides continuing normoventilation and hyperventilation, several degrees of hypoventilation were instituted (V~A~ of 2.5, 1.5, 1, and 0.5 L.min^-1^), and the course of F~VRG~ was observed. An increase in F~VRG~ \>0.3 MAC was considered to be evidence of rehypnotization.

Results
=======

Time for F~VRG~ to reach 0.3 MAC with normoventilation was 14 min 42 s with isoflurane, 9 min 12 s with sevoflurane, and 6 min 12 s with desflurane. With hyperventilation these times were reduced to 10 min 18 s, 7 min 30 s, and 5 min 24 s, respectively. Hyperventilation therefore reduced recovery times by 30, 18, and 13% for isoflurane, sevoflurane, and desflurane, respectively (Figure [1](#F1){ref-type="fig"}).

![**F**~**VRG**~**during emergence.** F~VRG~ (partial pressure in the vessel rich group, representing the central nervous system) of desflurane (DES), sevoflurane (SEVO) and isoflurane (ISO) versus time during emergence with normoventilation (NV) and hyperventilation (HV). The first data point is the value of F~VRG~ at the moment F~A~ (partial pressure in the alveoli) reaches 0.3 MAC (MACawake).](1471-2253-12-22-1){#F1}

After normoventilation during washout, subsequent hypoventilation with desflurane slowed the further decline in F~VRG~, but only severe hypoventilation (V~A~ 0.5 L.min^-1^) resulted in rehypnotization (Figure [2](#F2){ref-type="fig"}A). With sevoflurane, similar observations were made except that not only V~A~ of 0.5 but also 1 L.min^-1^ resulted in rehypnotization (Figure [2](#F2){ref-type="fig"}B). With isoflurane, even mild hypoventilation (V~A~ 2.5 L.min^-1^) resulted in rehypnotization, and V~A~ of 1.5, 1, and 0.5 L.min^-1^ all resulted in a much faster and larger increase in F~VRG~ (Figure [2](#F2){ref-type="fig"}C).

![**Effect of several degrees of hypoventilation on F**~**VRG**~**during emergence.** F~VRG~ (partial pressure in the vessel rich group, representing the central nervous system) of desflurane (**Figure**[2](#F2){ref-type="fig"}**A**), sevoflurane (**Figure**[2](#F2){ref-type="fig"}**B**) and isoflurane (**Figure**[2](#F2){ref-type="fig"}**C**) versus time after emergence with variable alveolar minute ventilation (V~A~). NV = normoventilation; HV = hyperventilation. Any F~VRG~ data point that is above the thick horizontal line representing MACawake indicates rehypnotization.](1471-2253-12-22-2){#F2}

In addition, initial hyperventilation before instituting hypoventilation raised F~VRG~ even higher compared to normoventilation with isoflurane (Figure [2](#F2){ref-type="fig"}C), but not with the less soluble agents (Figure [2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}B).

Discussion
==========

Emergence from general anesthesia with a potent inhaled anesthetic occurs in 50% of the patients when F~CNS~, reflected in the GasMan^®^ program by F~VRG~, decreases below the threshold MACawake, which we defined as 0.3 MAC. The driving force to decrease F~VRG~ is a decrease in F~a~, and GasMan^®^ assumes that at the level of the alveolocapillary interface there is virtual instantaneous equilibration between blood and alveolar gas so that F~A~ = F~a~. Therefore it is the decrease in F~A~ that results in the F~CNS~ to decrease.

Increasing V~A~ promotes the elimination of agent from the lungs, and results in a faster reduction of F~A~ and subsequently of F~a~ and F~VRG~; as a consequence, emergence will be faster. In this GasMan^®^ simulation, increasing V~A~ resulted in a small effect on emergence time with desflurane and a larger effect on emergence time with isoflurane. The effect on emergence time with sevoflurane was intermediate (Figure [1](#F1){ref-type="fig"}). This effect of solubility on emergence time with hyperventilation has been predicted \[[@B6],[@B7]\], and can be explained by the clearance formula \[[@B12]\]: clearance is more affected by V~A~ (and Q) for the higher soluble agents (Table [2](#T2){ref-type="table"}).

$$\mathbf{C}\mathbf{l}\mathbf{e}\mathbf{a}\mathbf{r}\mathbf{a}\mathbf{n}\mathbf{c}\mathbf{e} = \frac{1}{1 + \frac{\lambda_{B/G} \times Q}{V_{A}}}$$

###### 

**Clearance with changing Q and V**~**A**~**(based on the clearance formula)**

  **Q (L.min**^**-1**^**)**   **5**    **5**   **5**   **2.5**   **10**
  --------------------------- ------- ------- ------- --------- --------
  V~A~ (L.min^-1^)            5         2.5     10        5        5
  Clearance desflurane        0.70     0.54    0.83     0.83      0.54
   clearance (% baseline)               77%    117%     117%      77%
  Clearance sevoflurane       0.61     0.43    0.75     0.75      0.43
   clearance (% baseline)               72%    125%     125%      72%
  Clearance isoflurane        0.43     0.28    0.61     0.61      0.28
   clearance (% baseline)               64%    139%     139%      64%

Q: cardiac output; V~A~: alveolar minute ventilation.

In clinical practice, hyperventilation results in hypocarbia, and this will reduce Q~CNS~. A lower Q~CNS~ will reduce the removal of the agent from the CNS, and thereby will delay emergence \[[@B4]\]. Therefore, unless action is taken to avoid hypocarbia, hyperventilation is not going to be very helpful in reducing emergence time. In GasMan^®^, however, hyperventilation does not result in hypocarbia and therefore Q~CNS~ is maintained, and therefore this program lends itself well to simulate isocapnic hyperventilation in patients. Our observations therefore suggest that hyperventilation techniques that include methods to avoid hypocarbia to shorten emergence time have only a marginal benefit with modern agents.

Despite the predictions that hyperventilation has little effect on emergence time with poorly soluble agents, there has been a resurgent interest in the use of hyperventilation to hasten recovery from general anesthesia, even with the less soluble agents \[[@B1]-[@B5]\]. These clinical studies suggest that isocarbic hyperventilation does shorten emergence. However, there may be some methodological issues with some of these clinical studies. Vesely reported a shortened emergence with isoflurane when isocapnic hyperventilation was used \[[@B1]\], and this is indeed what is expected: isocapnic hyperventilation reduces emergence time according to the effect of V~A~ on eliminating anesthetic from the alveoli, and this was confirmed by our simulation with GasMan^®^. However, the effect of hyperventilation may have been less impressive if the control group would not have been hypoventilated during the initial part of emergence, which could have delayed emergence \[[@B1]\]: the authors allowed hypoventilation to occur during the initial phase of emergence in order to increase end-expired CO~2~, thereby stimulating the return of spontaneous ventilation. Ideally the control group should have been normoventilated throughout the emergence period because even short episodes of near-apnea may result in a rapid rise of F~VRG~\[[@B13]\]. A second study from the same group reported a similar reduction in emergence time with isocapnic hyperventilation when sevoflurane was used \[[@B5]\]. This is not expected: because sevoflurane is less soluble than isoflurane, isocapnic hyperventilation is supposed to have less effect on emergence time with this agent. Once more, the authors allowed relative hypoventilation to occur in the control group. Sakata reported that concurrent hyperventilation and rebreathing to induce hypercarbia significantly shortens recovery times \[[@B2],[@B3]\]. They used activated charcoal to prevent rebreathing of the potent inhaled anesthetic yet allow CO~2~ rebreathing. Surprisingly, they reported the same proportional decrease in recovery time for sevoflurane and desflurane (52% and 64%, respectively) \[[@B3]\]. Unfortunately, in the control group the patients were hypocarbic, which could have affected recovery time through its effects on Q~CNS~: the effect of hypocarbic vs. hypercarbic hyperventilation on recovery time has been clearly demonstrated by Gopalakrishnan: animals with hypercarbia had shorter emergence times than animals with hypocarbia \[[@B4]\].

Our GasMan^®^ simulation shows that hypoventilation after initial recovery not just reduces the speed of reduction in F~VRG~, but can actually increase F~VRG~ above MACawake values, resulting in rehypnotization. Lower blood and tissue solubility of the agent reduces the risk of rehypnotization when hypoventilation occurs. Eger has stated that recovery is faster with agents with lower solubility and that isocapnic hyperventilation can hasten recovery \[[@B7],[@B10],[@B14]\], and that hypoventilation can result in a rise in F~A~\[[@B7]\], but we believe our observations regarding the effects of subsequent hypoventilation on rehypnotization have not been described in such detail before. Rehypnotization is caused by a larger amount of agent brought into the alveoli from the peripheral tissues with venous blood than the amount of agent that is removed from the alveoli by V~A~; when F~A~ \>MACawake, rehypnotization will eventually occur. The amount of agent delivered to the alveoli depends on the amount of agent released by each tissue group, and agents with higher tissue solubility may result in a larger rise in F~A~ than agents with a lower solubility. With desflurane, the low tissue solubility results in relatively less desflurane returned to the alveoli than is cleared by the lungs even in the presence of mild-moderate hypoventilation, but with isoflurane relatively more agent is released by the tissues, and therefore even mild hypoventilation results in rehypnotization.

Although initial hyperventilation could be beneficial to speed up recovery with more soluble agents (isoflurane), it unfortunately also increases the risk of rehypnotization when subsequent hypoventilation occurs, and therefore this practice cannot be recommended. Hypoventilation occurs frequently immediately after general anesthesia due to an obtunded hypoxic respiratory drive \[[@B15]\], excessive use of narcotics, residual muscle paralysis, or partial upper airway obstruction.

Obviously these observations based on a simulation will have to be verified by well-controlled clinical studies. In addition, the effects of hypoventilation after recovery should be studied after less lengthy procedures where the muscle group is less saturated; we would expect relatively less effect of hypoventilation after recovery on the risk of rehypnotization. Also, effects of body habitus (more or less muscle and fat mass) deserve to be studied. We can speculate that an increase in the size of the muscle group increases the risk of rehyponotization with hypoventilation after recovery, because more agent will be made available by the muscle group for redistribution.

There is a lack of published clinical data on arterial partial pressures of potent inhaled anesthetic agents during emergence. One recent study found arterial plasma partial pressure of sevoflurane 30 min after cessation of sevoflurane administration to be 20% of original arterial partial pressure (Table [2](#T2){ref-type="table"} in reference 16) - this result is consistent with the finding in our simulation (0.38/2 = 19% of original F~VRG~) at 30 min in the sevoflurane group with mild hypoventilation (Figure [2](#F2){ref-type="fig"}) \[[@B16]\].

Conclusions
===========

In summary, isocarbic hyperventilation to speed up emergence is theoretically less effective for the modern, less-soluble agents. It may not be worth the effort at all with desflurane. In contrast to more soluble agents such as isoflurane, when hyperventilation is used with less soluble agents such as desflurane, the risk of subsequent rehypnotization when hypoventilation occurs is virtually non-existent. Well-controlled clinical studies are required to validate these simulations.
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